Table 4.

Cytogenetic abnormalities of AML patients stratified by age groups

	Total 325	Younger AML patients (n = 268)	Older AML patients (n = 57)	p value
Genes mutation total events (mean)	2.02	1.94	2.37	0.034*
TET2	164 (50.5%)	136 (50.7%)	28 (49.1%)	0.8238
ASXL1	62 (19.1%)	46 (17.2%)	16 (28.1%)	0.057#
CEBPA	56 (17.2%)	49 (18.3%)	7 (12.3%)	0.2758
FLT3	53 (16.3%)	45 (16.8%)	8 (14.0%)	0.609
DNMT3A	44 (13.5%)	35 (13.1%)	9 (15.8%)	0.584
NRAS	39 (12.0%)	32 (11.9%)	7 (12.3%)	0.943
NPM1	36 (11.1%)	29 (10.8%)	7 (12.3%)	0.7498
RUNX1	25 (7.7%)	17 (6.3%)	8 (14.0%)	0.0478*
IDH1	22 (6.8%)	19 (7.1%)	3 (5.3%)	0.618
IDH2	22 (6.8%)	13 (4.9%)	9 (15.8%)	0.0028**
KIT	19 (5.8%)	18 (6.7%)	1 (1.8%)	0.147#
ETV6	9 (2.8%)	7 (2.6%)	2 (3.5%)	0.7079
TP53	9 (2.8%)	4 (1.5%)	5 (8.8%)	0.0024**
WT1	8 (2.5%)	6 (2.2%)	2 (3.5%)	0.574
U2AF1	8 (2.5%)	6 (2.2%)	2 (3.5%)	0.574
PHF6	8 (2.5%)	6 (2.2%)	2 (3.5%)	0.574
EZH2	7 (2.2%)	7 (2.6%)	0 (0.0%)	NA
TTN	7 (2.2%)	5 (1.9%)	2 (3.5%)	0.4378
SF3B1	7 (2.2%)	3 (1.1%)	4 (7.0%)	0.005**
SRSF2	4 (1.2%)	3 (1.1%)	1 (1.8%)	0.693
JAK2	3 (0.9%)	2 (0.7%)	1 (1.8%)	0.4698
DNA methylation (frequency, %)	252 (77.5%)	202 (75.4%)	50 (87.7%)	0.0425*
RNA spliceosome (frequency, %)	20 (6.2%)	12 (4.5%)	8 (14.0%)	0.006399**
Chromatin remodelling (frequency, %)	69 (21.2%)	53 (19.8%)	16 (28.1%)	0.164379#
Transcriptional deregulation (frequency, %)	89 (27.04%)	72 (26.9%)	17 (28.8%)	0.649175
Activated signalling (frequency, %)	118 (36.3%)	101 (37.7%)	17 (28.8%)	0.262345

^#Although there was difference, but no statistically significance was observed between two groups

*Statistically difference (p < 0.05) was obseved between two groups

**Statistically singnificant difference (p < 0.01) was obseved between two groups